The Inventurus Knowledge Solutions IPO is an exciting opportunity in the healthcare services sector, providing investors with a chance to own a stake in a rapidly growing company. This article offers a detailed overview of the IPO, highlighting essential details, financials, and strategic insights to help investors make informed decisions.
IPO Highlights
Issue Size: ₹2,497.92 crores (18.79 million shares) through a 100% Offer for Sale.
IPO Dates: Opens on December 12, 2024, and closes on December 16, 2024.
Listing Date: Tentatively on December 19, 2024, on BSE and NSE.
Price Band: ₹1265 to ₹1329 per share.
Lot Size: Minimum of 11 shares; retail investors can invest starting from ₹14,619.
IPO Reservation Categories
Qualified Institutional Buyers (QIB): Minimum 75% of the offer.
Non-Institutional Investors (NII): Maximum 15% of the offer.
Retail Investors: Maximum 10% of the offer.
About Inventurus Knowledge Solutions
Inventurus Knowledge Solutions Limited, also known as IKS Health, was incorporated in 2006. The company specializes in providing healthcare enterprises with services like medical documentation management, virtual medical scribing, and clinical support. These solutions aim to streamline administrative tasks for healthcare providers, enabling them to focus more on patient care.
Competitive Strengths
Comprehensive Platform: A one-stop solution catering to both outpatient and inpatient care services.
Strong Client Base: Over 778 healthcare organizations, including industry leaders like Mass General Brigham Inc. and Texas Health Care PLLC.
Technology-Driven: Leveraging digital transformation and automation to enhance operational efficiency.
Scalable Model: Sustainable growth with cross-selling opportunities across diverse healthcare needs.
Financial Performance
Inventurus Knowledge Solutions has demonstrated strong financial growth:
Revenue Growth: 75.25% increase from FY23 to FY24.
Profit After Tax (PAT): Grew by 21.38% in the same period.
Key Ratios:
Return on Equity (ROE): 32%.
Return on Capital Employed (ROCE): 31.56%.
PAT Margin: 20.38%.
